搜尋結果
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
2024年6月28日 · China is the third country to launch LEQEMBI following the United States and Japan. LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in AD, thereby reducing both Aβ protofibrils and Aβ plaques in the brain.
AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen.
Eisai Co., Ltd. announced that the following Directors and Corporate Officers for FY2024 were appointed by resolutions at the 112th Ordinary General Meeting of Shareholders and subsequent Board of Directors meeting held today. Directors (*Outside Directors) Board of Directors.
Eisai is distributing the product in China and conducting information provision activities through specialized Medical Representatives, while also working to build a unique early AD diagnosis and treatment pathway that combines online and offline services.
Eisai Announces Status Relating to Acquisition of Own Shares. Eisai Co., Ltd. (“the Company”) announced today that it has acquired its own shares based on Article 40 of its Articles of Incorporation pursuant to the provisions of Article 459, paragraph 1 of the Companies Act.
Eisai Co., Ltd. (“the Company”) resolved at its Board of Directors meeting held on May 15, 2024, to appoint a new Representative Corporate Officer, effective June 14, 2024 as described below.
